You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)貼片產品上市申請已獲歐盟受理
阿思達克 05-18 12:22
綠葉製藥(02186.HK)公布,旗下創新藥物利斯的明多天貼片於歐洲境內的上市申請已獲歐盟主管部門受理。該產品是針對老年性癡呆的創新給藥途徑產品。

該產品是由公司子公司綠葉德國的透皮貼片研究及開發平台開發,針對中樞神經系統疾病的重點產品。綠葉德國曾為美國和歐洲市場開發利斯的明單天貼片,擁有產品研發成功的良好記錄。除德國以外,公司亦準備在歐洲其他國家、中國、美國、日本及其他國家註冊該產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account